Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive–compulsive disorder
- 27 July 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 27 (5), 645-651
- https://doi.org/10.1017/s1092852921000687
Abstract
ObjectiveObsessive–compulsive disorder (OCD) is a severe psychiatric disorder characterized by its heterogeneous nature and by different dimensions of obsessive–compulsive (OC) symptoms. Serotonin reuptake inhibitors (SRIs) are used to treat OCD, but up to 40% to 60% of patients do not show a significant improvement with these medications. In this study, we aimed to test the impact of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on the efficacy of antidepressants in OCD overall, and in relation to the different OC dimensions.MethodsIn a 6-month prospective treatment study, 69 Caucasian OCD patients were treated with escitalopram for 24 weeks or with escitalopram for 12 weeks followed by paroxetine for an additional 12-week period. Patients were genotyped and assessed for treatment response. The main clinical outcomes were improvement of the Yale-Brown Obsessive–Compulsive Scale score and in different OC symptom dimension scores.ResultsThe Val/Val group comprised 43 (62%) patients, the Val/Met and Met/Met group comprised 26 (38%) patients. Forty-two patients were classified as responders at 12 weeks and 38 at 24 weeks; no significant association was found between BDNF Val66Met and SRIs response at 12 and 24 weeks. In analyses of the different OC symptom dimensions, the Met allele was associated with a slightly reduced score in the aggressive/checking dimension at 6 months (P = .048).ConclusionsOur findings do not support the usefulness of BDNF Val66Met genotyping to predict overall response to treatment with SRIs in OCD; they did however suggest a better outcome at 6 months for the aggressive/checking symptom dimension for patients carrying the Met allele.Keywords
This publication has 24 references indexed in Scilit:
- Neurotrophin regulation of neural circuit development and functionNature Reviews Neuroscience, 2012
- Consideration of the BDNF gene in relation to two phenotypes: Hoarding and obesity.Journal of Abnormal Psychology, 2011
- Serum levels of brain-derived neurotrophic factor in major depressive disorder: state–trait issues, clinical features and pharmacological treatmentMolecular Psychiatry, 2010
- Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorderJournal of Affective Disorders, 2010
- Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxineJournal of Psychiatric Research, 2009
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMolecular Psychiatry, 2008
- Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or VenlafaxineNeuropsychopharmacology, 2008
- A Multidimensional Model of Obsessive-Compulsive DisorderAmerican Journal of Psychiatry, 2005
- Variant Brain-Derived Neurotrophic Factor (BDNF) (Met66) Alters the Intracellular Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in Neurosecretory Cells and Cortical NeuronsJournal of Neuroscience, 2004
- The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal FunctionCell, 2003